This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Sientra | |
|---|---|
| Name | Sientra |
| Type | Public |
| Industry | Medical devices |
| Founded | 2007 |
| Headquarters | Santa Barbara, California |
| Key people | Erin O'Brien (CEO) |
| Products | Breast implants, tissue expanders, surgical instruments |
| Revenue | (see Financial Performance and Market Presence) |
Sientra
Sientra is a United States–based medical device company specializing in aesthetic and reconstructive plastic surgery implants and related products. The company operates in the medical device and healthcare industries, marketing silicone gel breast implants, tissue expanders, and surgical adjuncts to plastic surgeons and hospitals. Sientra's activities intersect with regulatory agencies, academic medical centers, and commercial competitors.
Sientra was founded in 2007 and developed products amid ongoing debates involving Food and Drug Administration, American Society of Plastic Surgeons, American Society of Aesthetic Plastic Surgery, and international regulatory frameworks such as the European Medicines Agency and Health Canada. Early corporate milestones included approvals, market entry, and partnerships with contract manufacturers and distributors, followed by a public listing that engaged investors from Nasdaq markets and venture financings involving private equity firms and strategic healthcare investors. The company's trajectory has paralleled developments at competitors such as Allergan (company), Establishment Labs, Mentor Worldwide LLC, and mergers and acquisitions trends seen in the portfolios of Johnson & Johnson, Medtronic, Stryker Corporation, and other medical device conglomerates. Sientra’s history intersects with surgical education programs at institutions like Johns Hopkins Hospital, Mayo Clinic, and Cleveland Clinic through product demonstrations and sponsored training.
Sientra’s product portfolio centers on silicone gel breast implants and tissue expanders used in aesthetic augmentation and post-mastectomy reconstruction. Comparable product classes are produced by Allergan (company), Mentor Worldwide LLC, Establishment Labs, and Polytech Health & Aesthetics. The company supplies surgical instruments, implant sizers, and patient education materials to plastic surgeons practicing at facilities such as Massachusetts General Hospital, Mount Sinai Hospital (Manhattan), and University of California, San Francisco Medical Center. Sientra markets implants across procedural settings defined by surgical societies like the American Society of Plastic Surgeons and clinical practice guidelines issued by bodies including the National Comprehensive Cancer Network. Sales channels include direct distribution, third-party distributors, and relationships with group purchasing organizations such as Premier (company) and Vizient, Inc..
Sientra’s products are subject to oversight by the Food and Drug Administration in the United States and analogous regulators internationally, including the European Medicines Agency and Health Canada. The company participates in post-market surveillance systems, adverse event reporting to the FDA’s Center for Devices and Radiological Health, and collaborates with clinical registries such as the National Breast Implant Registry and academic studies from institutions like Brigham and Women's Hospital and Stanford Health Care. Sientra adheres to quality management standards referenced by regulators and auditors such as International Organization for Standardization (ISO) frameworks and inspection regimes applied by state health departments and certification bodies. Safety considerations have involved interactions with patient advocacy groups, oncologic organizations like the American Society of Clinical Oncology, and professional guideline committees.
Sientra operates as a corporation with an executive leadership team and board of directors drawn from healthcare, finance, and medtech backgrounds. Senior leaders have included chief executive officers, chief financial officers, and medical affairs executives who previously held roles at companies such as Pfizer, Bausch Health, AbbVie, and Boston Scientific. The board has comprised independent directors with experience at institutions like Goldman Sachs, Morgan Stanley, and academic affiliations with Harvard Medical School, Stanford University School of Medicine, and University of Pennsylvania. Corporate governance practices follow reporting requirements under Securities and Exchange Commission rules and market disclosure norms on Nasdaq-listed companies.
Sientra’s financial performance reflects revenue from implant sales, gross margins influenced by manufacturing and supply chain arrangements, and costs related to research, marketing, and regulatory compliance. The company’s public financial reports and filings with the Securities and Exchange Commission detail quarterly results, capital structure, and shareholder composition involving institutional investors such as Vanguard Group, BlackRock, and other asset managers. Market presence competes with global medtech firms including Allergan (company), Mentor Worldwide LLC, Establishment Labs, and regional manufacturers in Europe and Asia. Strategic initiatives have sought to expand distribution, enter new international markets subject to approvals from regulators like the European Medicines Agency and Medicines and Healthcare products Regulatory Agency, and leverage partnerships with hospital systems such as Kaiser Permanente, HCA Healthcare, and academic medical centers.
Sientra has been involved in litigation, regulatory inquiries, and product-related legal claims typical of the medical device sector, including matters adjudicated in federal courts and arbitration forums. Such disputes have occurred against a backdrop of high-profile litigation involving breast implant manufacturers, regulatory actions by the Food and Drug Administration, and class-action suits represented by law firms noted for mass tort practice. Legal proceedings reference experts from academic centers like Columbia University Irving Medical Center and Yale School of Medicine and interact with tort law precedents in jurisdictions across the United States, Canada, and Europe. The company’s legal strategy interfaces with corporate governance, insurance provided by carriers such as Chubb Limited and AIG, and settlements or judgments reported in public filings.
Sientra supports and sponsors clinical studies, post-approval investigations, and investigator-initiated research conducted at academic institutions including Memorial Sloan Kettering Cancer Center, University of Texas MD Anderson Cancer Center, and University of Michigan Health System. Published outcomes and safety analyses appear in peer-reviewed journals where articles cite collaborators from Harvard Medical School, Stanford University School of Medicine, Johns Hopkins University, and international centers. Clinical evidence addresses implant performance, capsular contracture rates, reconstructive outcomes, and patient-reported outcome measures used by organizations such as the International Society of Aesthetic Plastic Surgery and the American Society of Plastic Surgeons. Ongoing research networks and registries aim to provide longitudinal data that inform guidance from regulatory bodies and professional societies.
Category:Medical device companies of the United States